Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions.

Filament To Begin Phase 2 Study On Botanical Psilocybin Drug For Meth Use Disorder

Clinical-stage natural psychedelic drug developer Filament Health Corp. (OTCQB: FLHLF) received FDA approval to conduct a Phase 2 clinical trial on the safety, tolerability and feasibility of using PEX010, the company’s botanical psilocybin drug candidate on individuals with Methamphetamine Use Disorder (MAUD.)

See also: Major Psychedelics Firm Is Studying Magic Mushrooms To Treat Meth Addiction

The investigator-initiated trial will take place at UCSF’s Translational Psychedelic Research Program (TrPR) and will assess the psychedelic therapy building on the fact that psilocybin has been shown to increase abstinence and reduce consumption in people with substance use disorders.

Co-founder and CEO Benjamin Lightburn said the company is "pleased to support this much-needed research” and added that this trial is the first to study naturally derived, non-synthetic psilocybin for MAUD.

See also: <a …

Full story available on